CASE REPORT article
Front. Med.
Sec. Pulmonary Medicine
Volume 12 - 2025 | doi: 10.3389/fmed.2025.1658583
Treatment of Advanced Lung Adenocarcinoma with EGFR L833V/H835L Compound Mutations Using Furmonertinib: Two Case Reports and Literature Review
Provisionally accepted
- Hebei Cancer Clinical Medical Research Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background:Lung cancer remains the leading cause of cancer-related mortality worldwide. With advancements in molecularly targeted therapies, Epidermal growth factor receptor (EGFR) mutations have emerged as critical therapeutic targets in advanced lung adenocarcinoma. However, the EGFR p.L833V/p.H835L compound mutations are relatively uncommon, and their clinical characteristics and therapeutic response to EGFR tyrosine kinase inhibitors (TKIs) remain poorly defined.Case Presentation:This study reports two cases of advanced lung adenocarcinoma harboring the EGFR p.L833V/p.H835L compound mutation, both treated with furmonertinib. Case 1 was a 62-year-old male, and Case 2 was a 61-year-old female, both diagnosed through tissue biopsy and next-generation sequencing (NGS).Following treatment, both patients achieved partial response (PR), with progression-free survival (PFS) of 29 months and not available (NA, >12 months), respectively, demonstrating good tolerability.Result:Furmonertinib appears to be an effective treatment for advanced lung adenocarcinoma with EGFR p.L833V/p.H835L compound mutations. Conclusion: This study further supports the therapeutic potential of furmonertinib in EGFR-mutant lung cancer.
Keywords: Lung Adenocarcinoma, EGFR mutation, p.L833V/p.H835L Compound Mutation, furmonertinib, case report
Received: 02 Jul 2025; Accepted: 04 Aug 2025.
Copyright: © 2025 Wang, Shi, Liu, Liu, Liu, Han, Gao, Han and Xie. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Shaonan Xie, Hebei Cancer Clinical Medical Research Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.